抑郁症缓解后停用抗抑郁药的系统综述与荟萃分析
该系统综述与荟萃分析纳入40项研究(n=8890),评估重性抑郁障碍急性期治疗缓解后继续使用原抗抑郁药与换用安慰剂相比的复发风险。结果显示抗抑郁药组复发率约20.9%,安慰剂组约39.7%(OR=0.38,95%CI 0.33-0.43,p<0.00001),提示继续维持治疗可显著降低复发风险,且SSRIs在疗效与可接受性间较均衡,灵活剂量调整效果更佳。
要点
- 缓解后继续使用原抗抑郁药较安慰剂显著降低复发风险(OR=0.38)。
- SSRIs在疗效与可接受性间较均衡,灵活剂量调整较固定剂量更有效。
- 缓解后继续治疗至少6个月仍显示持续获益,青少年复发与脱落率高于成人。
核心结论
- 为预防复发和治疗失败,推荐缓解后继续维持治疗并至少密切随访6个月。
研究设计与样本
- 系统综述与荟萃分析,纳入40项研究,总样本量n=8890,采用随机效应模型计算合并OR及95%CI。
主要发现
- 抗抑郁药组复发率20.9%,安慰剂组39.7%,OR=0.38(95%CI 0.33-0.43,p<0.00001)。
- 三环类复发率差25.3%(OR=0.30,95%CI 0.17-0.50,p<0.00001),SSRIs差21.8%(OR=0.33,95%CI 0.28-0.38,p<0.00001),其他新型药物差16.0%(OR=0.44,95%CI 0.36-0.54,p<0.00001)。
- 灵活剂量方案OR=0.30(95%CI 0.23-0.48,p<0.00001),固定剂量方案OR=0.41(95%CI 0.36-0.48,p<0.00001)。
- 缓解后持续治疗超过6个月的研究中,抗抑郁药组复发率20.2%,安慰剂组37.2%(OR=0.40,95%CI 0.29-0.55,p<0.00001)。
- 维持6个月OR=0.41(95%CI 0.35-0.48,p<0.00001;19.6% vs 37.6%),超过1年OR=0.35(95%CI 0.29-0.41,p<0.00001;19.9% vs 39.8%)。
关键数值与推荐
- 抗抑郁药组与安慰剂组全因脱落率分别为43%和58%(OR=0.47,95%CI 0.40-0.55,p<0.00001)。
- 两组耐受性率均约4%。
- 青少年复发率(OR=0.32,95%CI 0.18-0.64,p=0.0010;41.0% vs 66.7%)及全因脱落率高于成人。
临床怎么用
- 缓解后应继续使用达到缓解的抗抑郁药进行维持治疗,以降低复发和治疗失败风险。
- SSRIs在疗效与可接受性间较均衡,可优先考虑;灵活剂量调整较固定剂量更有利于预防复发。
- 缓解后至少6个月内需密切随访,青少年患者应更关注复发与脱落风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A significant clinical issue encountered after a successful acute major depressive disorder (MDD) treatment is the relapse of depressive symptoms. Although continuing maintenance therapy with antidepressants is generally recommended, there is no established protocol on whether or not it is necessary to prescribe the antidepressant used to achieve remission. In this meta-analysis, the risk of relapse and treatment failure when either continuing with the same drug used to achieved remission or switching to a placebo was assessed in several clinically significant subgroups. The pooled odds ratio (OR) (±95% confidence intervals (CI)) was calculated using a random effects model. Across 40 studies (n = 8890), the relapse rate was significantly lower in the antidepressant group than the placebo group by about 20% (OR = 0.38, CI: 0.33-0.43, p < 0.00001; 20.9% vs 39.7%). The difference in the relapse rate between the antidepressant and placebo groups was greater for tricyclics (25.3%; OR = 0.30, CI: 0.17-0.50, p < 0.00001), SSRIs (21.8%; OR = 0.33, CI: 0.28-0.38, p < 0.00001), and other newer agents (16.0%; OR = 0.44, CI: 0.36-0.54, p < 0.00001) in that order, while the effect size of acceptability was greater for SSRIs than for other antidepressants. A flexible dose schedule (OR = 0.30, CI: 0.23-0.48, p < 0.00001) had a greater effect size than a fixed dose (OR = 0.41, CI: 0.36-0.48, p < 0.00001) in comparison to placebo. Even in studies assigned after continuous treatment for more than 6 months after remission, the continued use of antidepressants had a lower relapse rate than the use of a placebo (OR = 0.40, CI: 0.29-0.55, p < 0.00001; 20.2% vs 37.2%). The difference in relapse rate was similar from a maintenance period of 6 months (OR = 0.41, CI: 0.35-0.48, p < 0.00001; 19.6% vs 37.6%) to over 1 year (OR = 0.35, CI: 0.29-0.41, p < 0.00001; 19.9% vs 39.8%). The all-cause dropout of antidepressant and placebo groups was 43% and 58%, respectively, (OR = 0.47, CI: 0.40-0.55, p < 0.00001). The tolerability rate was ~4% for both groups. The rate of relapse (OR = 0.32, CI: 0.18-0.64, p = 0.0010, 41.0% vs 66.7%) and all-cause dropout among adolescents was higher than in adults. To prevent relapse and treatment failure, maintenance therapy, and careful attention for at least 6 months after remission is recommended. SSRIs are well-balanced agents, and flexible dose adjustments are more effective for relapse prevention.
引用
- Kato M, Hori H, Inoue T, et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry. 2020. PMID: 32704061. doi:10.1038/s41380-020-0843-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。